<DOC>
	<DOC>NCT00830115</DOC>
	<brief_summary>The aim of the study was to evaluate the effect of pantoprazole on sleep disorders in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease). The prevalence and intensity of the sleep disorders were evaluated by a standardized questionnaire. The study was expected to provide further data on safety and tolerability of pantoprazole.</brief_summary>
	<brief_title>Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Main inclusion criteria: Outpatients with erosive gastroesophageal reflux disease (eGERD) or nonerosive reflux disease (NERD) Main exclusion criteria: Criteria as defined in the respective Summary of Product Characteristics (Chapter 4.3)</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>PPI therapy</keyword>
	<keyword>Pantoprazole</keyword>
	<keyword>eGERD (Erosive Gastroesophageal Reflux Disease)</keyword>
	<keyword>NERD (Non-Erosive Reflux Disease)</keyword>
</DOC>